Posted by Michael Wonder on 09 Nov 2021
Plus Therapeutics receives FDA fast track designation for 186RNL targeted radiotherapeutic for leptomeningeal metastases
9 November 2021 - Plus Therapeutics today announced that the U.S. FDA has granted the Company fast track designation for Rhenium-186 NanoLiposome (186RNL) for the treatment of leptomeningeal metastases, a rare complication in which the disease spreads to the membranes surrounding the brain and spinal cord, affecting nearly 5% of people living with cancer.
The Company recently announced clearance of its investigational new drug application from the FDA, and expects to initiate patient accrual in the ReSPECT-LM Phase 1 dose escalation clinical trial of 186RNL in the fourth quarter of 2021.
